The Indian Pharmaceutical Market (IPM) clocked Rs 5948 crores in March 2014. It has grown at 3.9 per cent. Amongst the top 10, Lupin grew at 10.7 per cent followed by Alkem at 8.3 per cent and Emcure at six per cent. 32 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporates, Biocon has the highest growth of 45.8 per cent followed by Ajanta at 28.4 per cent and Apex at 26.2 per cent. Amongst the 11-20 ranked companies, Ipca has shown high growth at 23.3 per cent followed by Macleods at 17.4 per cent and Torrent at 16 per cent.
Sun as a company has seen 15.4 per cent growth in March 2014. Sun as a corporate now has a MS of 9.49 per cent for March 2014.
With Bonus Units at Full Value (Val in Crs) | ||||||||
Val in Crs | Rank | MAT Mar -14 | Mar-14 | |||||
COMPANY | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 75757 | 100.00 | 6.2 | 5948 | 100.00 | 3.9 | ||
| Sun Pharma | 1 | 1 | 4087 | 5.39 | 17.2 | 347 | 5.83 | 15.2 |
| Cipla | 2 | 2 | 3777 | 4.99 | 6.1 | 302 | 5.08 | 7.6 |
| Zydus Cadila | 3 | 3 | 3104 | 4.10 | 10.9 | 247 | 4.15 | 3.8 |
| Ranbaxy | 4 | 4 | 2987 | 3.94 | -1.4 | 218 | 3.66 | -9.2 |
| Glaxo | 5 | 5 | 2753 | 3.63 | -15.2 | 213 | 3.58 | -9.9 |
| Abbott HC | 6 | 7 | 2711 | 3.58 | 0.5 | 205 | 3.45 | -5.4 |
| Mankind | 7 | 6 | 2675 | 3.53 | 4.7 | 208 | 3.49 | -0.3 |
| Lupin | 8 | 8 | 2540 | 3.35 | 12.0 | 204 | 3.43 | 10.7 |
| Alkem | 9 | 10 | 2363 | 3.12 | 11.1 | 177 | 2.97 | 8.9 |
| Pfizer | 10 | 9 | 2207 | 2.91 | 3.6 | 179 | 3.01 | 4.0 |
| Macleods | 11 | 11 | 1980 | 2.61 | 9.2 | 167 | 2.81 | 17.4 |
| Sanofi India | 12 | 14 | 1935 | 2.55 | 1.3 | 141 | 2.37 | -4.9 |
| Intas | 13 | 12 | 1889 | 2.49 | 8.8 | 152 | 2.56 | 4.0 |
| Aristo | 14 | 13 | 1832 | 2.42 | 12.7 | 142 | 2.39 | 14.8 |
Indian companies have grown at 5.5 per cent versus -1.1 per cent for MNCs in March 2014. Amongst the top 50 in MNCs, MSD grew the highest at 13.5 per cent, followed by Allergan at 9.6 per cent and Merck at 9.5 per cent.
The DPCO 2013 containing molecules market was at –13.9 per cent whereas the non-DPCO market grew by 6.8 per cent resulting in an overall growth of 3.9 per cent for March 2014. The DPCO 2013 portfolio for GSK de-grew at 23.5 per cent and Ranbaxy de-grew by 24.2 per cent, whereas Sun Pharma in its DPCO 2013 portfolio de-grew at 10 per cent.
From therapy perspective 10 therapies have outgrown the IPM growth and two therapies have double digit growths. Respiratory market grew at 8.8 per cent, gastrointestinal market grew at 3.8 per cent whereas the anti-infectives de-grew at -3.3 per cent. The anti-diabetic market grows at 15.8 per cent and cardiac at 6.7 per cent in chronic business. The derma market grew by 9.2 per cent.
Val in Crs | MAT Mar 14 | Month Mar -14 | ||
Super Group | VAL IN CRS | GR% | VAL IN CRS | GR% |
| IPM | 75752 | 6.2 | 5947 | 3.9 |
| ANTI-INFECTIVES | 12584 | 0.6 | 921 | -3.3 |
| CARDIAC | 9396 | 9.1 | 761 | 6.7 |
| GASTRO INTESTINAL | 8518 | 5.8 | 661 | 3.8 |
| VITAMINS / MINERALS / NUTRIENTS | 6793 | 5.6 | 530 | 2.7 |
| RESPIRATORY | 5925 | 9.3 | 488 | 8.8 |
| PAIN / ANALGESICS | 5544 | 3.5 | 428 | 2.5 |
| ANTI DIABETIC | 5326 | 15.2 | 446 | 15.8 |
| NEURO / CNS | 4729 | 7.5 | 381 | 4.8 |
| GYNAECOLOGICAL | 4703 | 1.4 | 374 | 0.1 |
| DERMA | 4200 | 11.2 | 332 | 9.2 |
| OPHTHAL / OTOLOGICALS | 1375 | 8.3 | 112 | 5.1 |
| HORMONES | 1290 | 5.7 | 105 | 6.2 |
| VACCINES | 1115 | -1.5 | 81 | -15.5 |
| ANTI-NEOPLASTICS | 1038 | 28.2 | 87 | 14.5 |
| BLOOD RELATED | 915 | 2.7 | 69 | 0.7 |
| OTHERS | 909 | 5.9 | 74 | 5.1 |
| ANTI MALARIALS | 624 | 1.5 | 36 | 3.6 |
| SEX STIMULANTS / REJUVENATORS | 429 | 5.1 | 35 | 3.0 |
| STOMATOLOGICALS | 339 | 8.0 | 27 | 6.3 |
From regional perspective 15 regions have outgrown the IPM growth. The Odisha market grew the highest at 15.1 per cent followed by Jharkhand market at 10.4 per cent. Two regions had negative growths in March 2014.
The biggest molecule Amoxycillin + Clavulanic de-grew by 2.7 per cent, whereas Cefixime degrew at 9.1 per cent. The markets of Glimepiride + Metformin grew at 33.9 per cent, Vitamin- D grew by 26.4 per cent, Levetiracetam by 23.7 per cent, Rosuvastain by 22.7 per cent, Telmisartan by 17.6 per cent and Levocetirizine + Montelukast by 16.9 per cent.
Glycomet-GP grows at 26.3 per cent amongst the top 10 Brands. Amongst the top brands in the IPM, Lantus grew by 30 per cent, Telma by 16.6 per cent, Skinlite by 13.7 per cent, Aciloc by 15 per cent, Dexorange 10 per cent amongst top 25 brands. A total of 87 brands were launched in March 2014. Silodal D, Quinvaxem and Coerip are the top NIs for the month of March 2014.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharma market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
